Work

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Year: 2021

Type: article

Abstract: Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation–positive non–small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation–positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab. See related article by Yu et al., p. 992

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-20-4026

Author: Edward B. Garon

Institution: University of California, Los Angeles

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute